ID   Rh28/L-PAM
AC   CVCL_Y584
SY   Rh28 L-PAM; Rh28/LPAM; RH28/LPAM; Rh 28/LPAM; Rh28 PX11/LPAM; Rh-28 PX11/LPAM
DR   GEO; GSM1676360
DR   GEO; GSM1701690
DR   Wikidata; Q54950337
RX   PubMed=2890432;
RX   PubMed=23882450;
RX   PubMed=26351324;
CC   Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; LPAM; Alkeran).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8752 ! Rh28
SX   Male
AG   17Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 12
//
RX   PubMed=2890432;
RA   Horton J.K., Houghton P.J., Houghton J.A.;
RT   "Reciprocal cross-resistance in human rhabdomyosarcomas selected in
RT   vivo for primary resistance to vincristine and L-phenylalanine
RT   mustard.";
RL   Cancer Res. 47:6288-6293(1987).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//